Cancer News and Research

Latest Cancer News and Research

Diversity of intestinal stem cells is greater than previously thought

Tales from the crypt are supposed to be scary, but new research from Vanderbilt University, the HudsonAlpha Institute for Biotechnology and colleagues shows that crypts can be places of renewal too: intestinal crypts, that is. Intestinal crypts are small areas of the intestine where new cells are formed to continuously renew the digestive tract. By focusing on one protein expressed in our intestines called Lrig1, the researchers have identified a special population of intestinal stem cells that respond to damage and help to prevent cancer.

31 Mar 2012

New project to focus on role of Myc oncoproteins in B-cell lymphoma

The National Institutes of Health has awarded The Scripps Research Institute $2 million to study the role of a pathway in the development and maintenance of B-cell lymphoma, a type of cancer that begins in immune system and turns normal disease fighting cells into cancers. The disease affects immune cells known as lymphocytes, which are part of our white blood cells.

31 Mar 2012

Online virtual communities may effectively train patients in mind/body techniques

A small study from Massachusetts General Hospital (MGH) researchers found that online virtual communities may be an effective way to train patients in meditation and other mind/body techniques. The ability to learn and practice approaches that elicit the relaxation response - a state of deep rest that has been shown to alleviate stress-related symptoms - in a virtual environment could help surmount several barriers that can restrict participation.

31 Mar 2012

Center for Healthcare Informatics and Policy established at Weill Cornell Medical College

Weill Cornell Medical College announced today the establishment of the Center for Healthcare Informatics and Policy (CHiP) to improve health and healthcare through informatics and technology.

31 Mar 2012

Clinical findings from Transgenomic's NuclearMitome Test study on nuclear mitochondrial disorders

Transgenomic, Inc. today announced that Jeana DaRe, Ph.D., Assistant CLIA Laboratory Director at Transgenomic, presented clinical findings from patients tested for nuclear mitochondrial disorders using Transgenomic's NuclearMitome Test on Thursday, March 29, at the 2012 Annual Meeting of the American College of Medical Genetics (ACMG) in Charlotte, North Carolina.

31 Mar 2012

NanoString to launch 3 new products for nCounter Analysis System at AACR 2012

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it will launch three new products for the nCounter Analysis System at the American Association of Cancer Research (AACR) Annual Meeting 2012, March 31-April 4, in Chicago, Ill.

From NanoString Technologies 31 Mar 2012

State of Texas awards Asuragen $6.8M to pursue Next Generation Sequencing applications

Asuragen, Inc. announced today that the Company received notice of a $6.8 million commercialization award to pursue Next Generation Sequencing (NGS) applications from the State of Texas through the Cancer Prevention and Research Institute of Texas ("CPRIT").

31 Mar 2012

UH clinical trial to evaluate stool DNA testing for colon cancer

In a first-of-its-kind clinical trial, physician-scientists at University Hospitals (UH) Case Medical Center's Seidman Cancer Center and Case Western Reserve University School of Medicine are studying a promising new non-invasive technology for colon cancer screening. The four-year study is recruiting patients to compare the effectiveness of stool DNA (SDNA) testing with colonoscopy for detecting large colon polyps.

31 Mar 2012

Galectin Therapeutics fourth quarter net loss increases to $3.7 million

Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the full year and fourth quarter, ended December 31, 2011.

31 Mar 2012

Canadian regulatory body recommendation brings melanoma patients closer to life-extending drugs

The Melanoma Network of Canada is pleased that the Canadian regulatory body, pCODR (pan-Canadian Oncology Drug Review) has made an initial recommendation that includes positive clinical evaluations for the latest treatments for metastatic melanoma.

31 Mar 2012

Cambridge Heart fourth quarter total revenue decreases to $557,000

Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today reported results for its fourth quarter and full year ended December 31, 2011. Full financial statements and corresponding commentary can be found in the Company's Form 10-K, which will be filed with the Securities and Exchange Commission on March 30, 2012.

31 Mar 2012

Number of kidney cancer cases rises over 9,000 in Great Britain

The number of cases of kidney cancer diagnosed each year in Great Britain has risen over 9,000 for the first time, new figures from Cancer Research UK show today.

31 Mar 2012

Accuray, University of Heidelberg enter multi-year master research and collaboration agreement

Accuray Incorporated, the premier radiation oncology company, announced today the signing of a multi-year master research and collaboration agreement with the University of Heidelberg, a luminary research institution located in Heidelberg, Germany that contributes to the city's top international position in therapy, research and science.

31 Mar 2012

Abbott receives CE Marking for PLEX-ID instrument and assays

Abbott announced today it has obtained CE Marking (Conformite Europeene) in the European Union to market its rapid, high-throughput PLEX-ID instrument, along with three assays for use on the system: PLEX-ID Viral IC Spectrum, PLEX-ID BAC Spectrum BC and PLEX-ID Flu.

31 Mar 2012

Differentiating between sneezing due to cold and allergies

One of the problems that parents may have during the springtime is deciphering whether their children's sneezing is due to a cold or allergies.

31 Mar 2012

Mirada Medical, BioClinica partner to extend oncology clinical trials

BioClinica, Inc., a global provider of clinical trial management solutions, today announced a partnership with Mirada Medical, a leading provider of medical image analysis software. BioClinica will integrate Mirada's XD3 software solution into its imaging core lab technology to further enhance its PET capabilities and expertise for molecular imaging trials.

From Clario 31 Mar 2012

ImmunoGen commences IMGN901 Phase II evaluation for SCLC

ImmunoGen, Inc. today announced that it has initiated Phase II testing of its IMGN901 product candidate for first-line treatment of SCLC.

31 Mar 2012

FDA approves Roche's cobas p 630 pre-analytical instrument

Roche announced today the FDA approval of a new pre-analytical instrument that provides an integrated primary tube handling solution for its widely adopted automated molecular testing platform.

31 Mar 2012

Bionovo 2011 total revenues decrease to $0.3 million

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced financial results for the year ended December 31, 2011.

31 Mar 2012

Cancer patients with CDI may benefit from DIFICLIR drug

New data presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) demonstrate that in cancer patients with CDI, DIFICLIR(fidaxomicin) may offer significant benefits in terms of clinical cure, recurrence and sustained clinical cure.

31 Mar 2012

Cancer News and Research

Latest Cancer News and Research

Diversity of intestinal stem cells is greater than previously thought

New project to focus on role of Myc oncoproteins in B-cell lymphoma

Online virtual communities may effectively train patients in mind/body techniques

Center for Healthcare Informatics and Policy established at Weill Cornell Medical College

Clinical findings from Transgenomic's NuclearMitome Test study on nuclear mitochondrial disorders

NanoString to launch 3 new products for nCounter Analysis System at AACR 2012

State of Texas awards Asuragen $6.8M to pursue Next Generation Sequencing applications

UH clinical trial to evaluate stool DNA testing for colon cancer

Galectin Therapeutics fourth quarter net loss increases to $3.7 million

Canadian regulatory body recommendation brings melanoma patients closer to life-extending drugs

Cambridge Heart fourth quarter total revenue decreases to $557,000

Number of kidney cancer cases rises over 9,000 in Great Britain

Accuray, University of Heidelberg enter multi-year master research and collaboration agreement

Abbott receives CE Marking for PLEX-ID instrument and assays

Differentiating between sneezing due to cold and allergies

Mirada Medical, BioClinica partner to extend oncology clinical trials

ImmunoGen commences IMGN901 Phase II evaluation for SCLC

FDA approves Roche's cobas p 630 pre-analytical instrument

Bionovo 2011 total revenues decrease to $0.3 million

Cancer patients with CDI may benefit from DIFICLIR drug

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in